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ABSTRACT
Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for 
glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to 
a subset of patients. Recent insight into the heterogeneous nature of GBM suggests 
a more personalized approach to treatment may be necessary to overcome cancer 
drug resistance and improve patient care. These include novel therapies that can be 
used both alone and with TMZ to selectively reactivate apoptosis within malignant 
cells. For this approach to work, reliable molecular signatures that can accurately 
predict treatment responsiveness need to be identified first. Here, we describe the 
first proof-of-principle study that merges quantitative protein-based analysis of 
apoptosis signaling networks with data- and knowledge-driven mathematical systems 
modeling to predict treatment responsiveness of GBM cell lines to various apoptosis-
inducing stimuli. These include monotherapies with TMZ and TRAIL, which activate 
the intrinsic and extrinsic apoptosis pathways, respectively, as well as combination 
therapies of TMZ+TRAIL. We also successfully employed this approach to predict 
whether individual GBM cell lines could be sensitized to TMZ or TRAIL via the selective 
targeting of Bcl-2/Bcl-xL proteins with ABT-737. Our findings suggest that systems 
biology-based approaches could assist in personalizing treatment decisions in GBM 
to optimize cell death induction.
INTRODUCTION
Glioblastoma (GBM), the most common form of 
primary brain tumor in humans, is typically aggressive, 
highly infiltrative, and resistant to conventional therapy. 
Despite improvements in surgical technique and the 
addition of temozolomide (TMZ) to the armamentarium, 
patient median survival remains dismal at 14.6 months, 
with most experiencing tumor relapse within 7 months 
of treatment onset [1] and a large proportion gaining no 
survival advantage to TMZ therapy at all [2, 3]. When 
successful, this oral alkylating drug induces glioma 
cell death by causing DNA double strand breaks that 
eventually lead to growth arrest and activation of cellular 
apoptosis [4].
To date, the only significant prognostic marker of 
GBM patient response to TMZ is promoter methylation of 
the gene encoding for MGMT [5, 6]; specifically, promoter 
methylation has been identified as a feature of favorable 
outcome in patients undergoing TMZ therapy for both 
newly diagnosed GBM and recurrent disease [7]. In the 
elderly sub-population of patients, MGMT testing is now 
recommended for routine clinical decision making with 
regards to stratification of therapy; this follows the results 
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of two phase 3 clinical trials that clearly demonstrate 
‘unmethylated’ patients benefit more from radiotherapy 
alone while ‘methylated’ patients benefit more from 
TMZ chemotherapy alone [8, 9]. In the non-elderly 
sub-population of GBM patients, however, discordant 
responses between ‘methylated’ and ‘unmethylated’ sub-
groups of patients exist, indicating that the treatment 
decision to use TMZ in these patients should not be based 
on this biomarker alone. Nevertheless, MGMT testing 
has become commonplace for patient selection within 
clinical trials [6] [10–13] and is frequently requested as a 
prognostic biomarker during patient clinical workup [14].
Irrespective of patient responsiveness to TMZ, 
the dismal prognosis associated with GBM makes it 
clear that other therapeutic strategies are required, both 
as stand-alone treatment options and as sensitizing 
therapies that can be combined with TMZ to overcome 
current treatment resistance. In line with this, due to the 
extremely heterogeneous nature of these tumors [15, 16], 
it is becoming increasingly evident that such treatment 
strategies ought to be individualized and tailored to the 
needs of each GBM patient. Recent efforts in personalizing 
anti-cancer treatments have focused on therapies that 
selectively reactivate apoptosis within malignant cells, 
such as those that promote apoptosis via the Bcl-2 family 
of regulatory proteins and those that act by binding to 
death receptors expressed on the surface of the cell.
Tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL), the natural ligand for the apoptotic 
receptors, DR4 and DR5, is one anti-cancer therapy 
that has been gaining momentum in recent years [17, 
18]. Using extrinsic agents like TRAIL has two putative 
advantages over intrinsic agents: firstly, TRAIL can trigger 
apoptosis independently of p53, which is commonly 
mutated in primary (28%) and secondary (65%) GBM 
patients [19], contributing, in part, to TMZ resistance 
[20]; and secondly, TRAIL can kill cancer cells without 
conferring significant toxicity to normal cells [21, 22]. 
Several TRAIL-based therapies, including the human 
recombinant TRAIL ligand (dulanermin), which targets 
both DR4 and DR5, and agonistic antibodies against DR4 
(mapatumumab) and DR5 (drozitumab, lexatumumab, 
tigatuzumab, LBY-135, and conatumumab) have been 
assessed within clinical trials [17, 23]. Unfortunately, 
while these agents are reportedly well tolerated in patients, 
both alone and in combination with standard therapies, 
only isolated responses have been observed. It should 
be noted, however, that these trials involved no degree 
of patient pre-selection and thus may not reflect a true 
clinical evaluation of TRAIL-based therapies, which 
might be efficacious but only for a subset of patients.
With regards to GBM, most glioma cells are resistant 
to TRAIL monotherapy, although several promising 
combination treatments to overcome this resistance have 
been described [24–28]. Particularly encouraging in vitro 
and in vivo findings come from the combination of TRAIL 
and TMZ, which evoke concomitant stimulation of the 
intrinsic and extrinsic apoptotic pathways [29–31]. Used 
together, these agents should, in theory, enhance both the 
likelihood of apoptosis induction as well as the strength of 
the apoptotic signal. TMZ might also play the role of TRAIL 
‘sensitizer’, overcoming resistance by up-regulating the 
expression of death receptors, leading in turn to substantial 
caspase activation [29, 30]. Other mechanisms of TRAIL 
and TMZ resistance are shared, such as an up-regulation of 
anti-apoptotic and down-regulation of pro-apoptotic Bcl-2 
proteins and an over-expression of inhibitor of apoptosis 
(IAP) proteins [23, 32].
Small molecules that antagonize pro-survival Bcl-2 
proteins, namely BH3 mimetics, are currently under pre-
clinical and clinical evaluation as single agent anti-cancer 
therapies and as sensitizers to apoptosis-inducing drugs 
[33, 34]. One of the most advanced and well characterized 
small molecule inhibitors is the BH3 mimetic, ABT-737, 
which predominantly binds to Bcl-2 and Bcl-xL to induce 
or sensitize cells to apoptosis through the intrinsic pathway. 
As a single agent, ABT-737 has shown anti-tumor activity 
in GBM cells in vitro [35], while in concert with TRAIL, 
it has demonstrated efficacious results in an in vivo model 
of GBM [27]. Recently, ABT-737 has also been shown to 
sensitize gliomas cells to TMZ-induced apoptosis [36].
Despite these promising studies, molecular marker 
signatures that could facilitate reliable predictions on 
the responsiveness of individual GBM cases to TMZ 
and TRAIL alone or in combination currently do 
not exist. Likewise, tools to predict ABT-737-based 
sensitization of GBM cells to TMZ or TRAIL have not 
yet been developed. Here, we addressed these problems 
in a first pre-clinical proof-of-principle study in which 
we merged quantitative experimental studies with data- 
and knowledge-driven mathematical system modeling to 
predict treatment responsiveness of GBM cell lines.
RESULTS
Defining and parameterizing functional groups 
of cell death regulators for knowledge- and  
data-driven systems modeling
We previously demonstrated that a knowledge- and 
data-driven mathematical modeling approach is capable 
of generating reliable predictions of melanoma cell line 
responsiveness to both TRAIL- and genotoxic drug-
induced cell death, outperforming classical statistical 
procedures [37]. As part of this approach, biological 
pathway information on linear and non-linear interplay 
between cell death regulatory proteins is integrated into 
data obtained from quantitative measurements of these 
proteins. This is achieved by defining “functional groups 
(FGs)” in which multiple proteins are related to each other 
by simple arithmetic rules (sums, products, or ratios of a 
small number of proteins), multivariate statistical analysis, 
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and the application of pattern recognition algorithms [37–
39]. To apply this approach to the TRAIL- and TMZ-based 
treatments in GBM, the relevant signaling pathways and 
the respective FGs first needed to be defined.
The apoptosis pathway activated by TRAIL is well 
characterized and depicted in Figure 1A. Briefly, TRAIL 
binds to death receptors, DR4 and DR5, on the surface 
of the cell, resulting in the recruitment of the adaptor 
protein, Fas-associated death domain (FADD), through 
death effector domain (DED) interactions. FADD, in turn, 
recruits pro-caspase-8, pro-caspase-10 and/or cellular-
FLIP (cFLIP), thereby forming the multi-protein death-
inducing signaling complex (DISC) [40]. Pro-caspase-8 
recruitment to the DISC results in its autocatalytic 
processing to the active caspase-8 enzyme; however, 
c-FLIP proteins can inhibit this process. If activated, 
caspase-8 can subsequently go on to activate effector 
caspases such as caspase-3 to execute the extrinsic 
apoptotic pathway [41]. Alternatively, caspase-8 can 
activate the intrinsic pathway via cleavage of the BH3-
only protein, Bid. The truncated active form of Bid, 
tBid, engages with Bax or Bak to induce mitochondrial 
outer membrane permeabilisation (MOMP) and release 
of cytochrome c and second mitochondria-derived 
activator of caspases (SMAC) into the cytosol [42]. This 
mitochondrial pathway of apoptosis, which involves 
additional BH3-only proteins, such as Bim, Puma and 
Noxa [43, 44], is also the entry point for cell death signals 
triggered by chemotherapeutics like TMZ [4, 45–48]. 
The function of BH3-only proteins and activated Bax or 
Bak is antagonized by the anti-apoptotic Bcl-2 family 
proteins, Bcl-2, Bcl-xL and Mcl-1. Once in the cytosol, 
cytochrome c interacts with apoptotic protease activating 
factor 1 (Apaf-1) to form the heptameric backbone of the 
apoptosome complex, which in turn recruits and activates 
caspase-9 [49]. At the same time, SMAC neutralizes 
the caspase-inhibitory function of X-linked inhibitor 
of apoptosis protein (XIAP) to assist in the ultimate 
activation of effector caspases like caspase-3 [50].
We used this knowledge of pathway topology to 
group the above-mentioned proteins into FGs based on their 
relationships within the signaling network (Figure 1B). For 
example, we grouped together Bcl-2, Bcl-xL and Mcl-1 by 
adding their nM amounts since these represent functionally 
redundant antagonists of Bax and Bak. Similarly, we grouped 
together Bax and Bak since they form the mitochondrial pores 
leading to MOMP. The BH3-only proteins, Bid, Bim, Puma, 
and Noxa, were kept as separate variables for a number 
of reasons. Firstly, Bid plays an essential role in driving 
the activation of the mitochondrial pathway of apoptosis, 
specifically in response to extrinsic pathway stimulation; 
therefore, functionally, Bid is largely separate from the other 
BH3-only proteins. Secondly, the respective relevance and 
individual importance of Bim, Puma and Noxa in regulating 
the TMZ-induced intrinsic pathway of apoptosis is still a 
matter of debate [51]. Furthermore, since these BH3-only 
proteins may need to be transcriptionally induced or post-
translationally modified in response to TMZ, either alone or 
in combinations, the relevance of their baseline expression 
levels with regards to determining cell death responsiveness 
is not yet clear [51–53]. It is also possible that these proteins 
functionally differ in their capacity to activate/antagonize 
pro- and anti-apoptotic Bcl-2 family proteins [54, 55]. Thus, 
keeping these proteins as separate variables allowed us to 
better understand their respective impact on the model’s 
performance. Of note, in the subsequent results we did not 
observe a notable improvement in model performance when 
merging these proteins into one FG (not shown). To define 
the caspase-9-activating apoptosome complex, we multiplied 
the protein concentrations of Apaf-1 and caspase-9; 
this multiplication ensured that the value for this group 
approached zero when either Apaf-1 or caspase-9 expression 
was low or absent. We applied the same reasoning to the 
grouping of DR4, DR5 and FADD; this group represented 
the DISC. FGs of apoptotic caspases and their antagonists 
(cFLIP and caspase-8; XIAP and caspase-3) were defined as 
ratios. SMAC remained as a single protein and accordingly 
was kept as an individual variable.
To parameterize these 11 FGs with protein data, 
we carried out quantitative flow cytometry to determine 
the cell surface expression of death receptors 4 and 5 as 
well as quantitative immunoblotting to determine the 
relative protein expression of the other 17 key players of 
the apoptotic pathways activated by TRAIL and TMZ 
(Supplementary Table S1). An overview, based on a total 
of 627 quantifications in 11 cell lines, is provided in Figure 
1C. The resulting quantities for the FGs are provided in 
Supplementary Table S2. The cell lines chosen for this 
study included both commercially available cell lines, A172, 
U87, U251, U343, and U373 and a cohort of lines derived 
from patient GBMs, including both primary (MZ18, MZ51, 
MZ294, MZ327) and recurrent (MZ256, MZ304) tumors. All 
of the commercially available lines expressed a methylated 
MGMT promoter whilst among the patient derived cell lines, 
MZ18, MZ51 and MZ294 expressed a methylated promoter 
and MZ304, MZ256 and MZ327 expressed an unmethylated 
promoter. Of note, statistical analysis comparing the relative 
expression of apoptotic proteins, as listed in Supplementary 
Table S1, in “methylated” versus “unmethylated” cell lines 
revealed no relationship between protein expression profiles, 
methylation status and response to treatment (not shown).
Functional groups of apoptosis regulators 
in GBM cell lines can be associated with cell 
death responsiveness to TMZ and TRAIL 
monotherapy
Following the parameterization of the FGs, these 
data were analyzed to determine if any relationship existed 
between FG values and the responsiveness of each cell line 
to TMZ or TRAIL. First, we applied a principal component 
analysis (PCA) to the FG data. This statistical procedure 
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allowed us to accumulate the variance observed in the 11 
FGs in the 11 cell lines in a lower number of independent 
dimensions, referred to as principal components (PCs) 
(Figure 2A). The variance explained by the respective PCs 
indicates that the first 4 PCs needed to be retained for the 
subsequent analyses to capture approximately 70% of the 
data variance of the original data set, and all subsequent 
analyses were therefore conducted in this 4D PC space. 
Each PC is defined by distinct contributions of the 
different FGs, according to specific weighting coefficients 
for the FGs (Figure 2B, Supplementary Table S3).
For visualization purposes, the cell-line specific 
values of the FGs, multiplied with the FG-specific 
coefficients in the first three 3 PCs, allowed us to position 
the 11 GBM cell lines within a three dimensional PC space 
(Figure 2C). The position of the individual cell lines in 
the PC space is therefore associated with their respective 
individual protein expression profiles. The distribution 
of the cell lines within the PC space demonstrated that 
the cell lines did not form spatially separated clusters, 
indicating a high degree of heterogeneity between the 
GBM cell lines (Figure 2C). Additional information on 
this procedure is provided in the methods section and the 
published literature [37].
Next, we asked whether the PC space, and 
therefore the protein composition of the apoptosis 
signaling network, contains information on whether the 
cell lines are responsive to TMZ or TRAIL. To this end, 
we first experimentally measured cell viability following 
TMZ or TRAIL treatment in all cell lines (Figure 2D). 
Our data showed that the responsiveness of the cell lines 
to TMZ or TRAIL varied substantially across the panel 
and also that individual cell lines frequently responded 
differently to TMZ or TRAIL. Furthermore, we also 
noted that very few cell lines responded well to these 
treatments (Figure 2D). Previous work from our group 
has highlighted that a reduction in cell survival in TMZ 
responsive cell lines, U251 and U343, correlates with 
activation of the intrinsic apoptotic cell death pathway, 
as demonstrated by a significant increase in the number 
of condensed nuclei and AnnexinV staining, as well as 
procaspase-3 activation and PARP cleavage; we also 
showed that such cell death could be suppressed by 
caspase inhibition with zVAD-fmk and that no such 
responses were evident in TMZ-resistant cell lines 
[56]. To confirm that the TRAIL-sensitive cell lines 
were undergoing apoptosis via the extrinsic pathway, 
we examined the processing of procaspase-8 in the 
TRAIL-sensitive cell line, A172; cleavage of caspase-8 
was clearly detected 24 h post TRAIL treatment 
(Supplementary Figure S1A). We also examined the 
effect of TRAIL treatment on the executioner caspase, 
caspase-3, and found that TRAIL treatment also led to 
the cleavage of pro-caspase-3 after 24 h (Supplementary 
Figure S1A). Activation of both caspase-8 and caspase-3 
was prevented by the combined presence of zVAD-fmk 
and TRAIL (Supplementary Figure S1A). Furthermore, 
we detected a significant increase in AnnexinV positive 
cells following TRAIL treatment (Supplementary Figure 
S1B), which was also prevented by zVAD-fmk. None 
of these events were evident in the TRAIL-resistant cell 
line, MZ304 (Supplementary Figures S1A, S1B).
Figure 1: Coding and parameterizing functional groups of apoptosis signaling proteins for knowledge- and data-
driven systems modeling. A. Pathway diagram for intrinsic and extrinsic apoptosis pathways elicited by TMZ and TRAIL, respectively. 
B. Grouping of apoptosis signaling proteins into functional groups by simple arithmetic operations. C. Relative levels of protein expression 
within the GBM cell line panel. Circles summarize 627 quantifications, while circle sizes are proportional to the protein quantities 
determined from n = 3 independent experiments. Green and red indicate anti- and pro-apoptotic proteins, respectively. Protein expression 
amounts are provided in Supplementary Table S1. The resulting FG values are provided in Supplementary Table S2.
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Figure 2: Functional groups of cell death regulators highlight an association between protein expression profiles and 
cell survival following TMZ and TRAIL treatment. A. A principal component analysis (PCA) was applied to the functional 
groups of the GBM cell line panel. Results are shown as a scree plot. Bar graphs show the contribution of each principal component (PC) 
toward explaining the data variance. B. Bar graphs show the coefficients for all functional groups in the first four PCs. Coefficient values 
are provided in Supplementary Table S3. C. Graphical illustration of the distribution of GBM cell lines along the first three PCs. Circle 
sizes decrease with distance from the observer to aid 3D visualization. D. Cell survival following TMZ and TRAIL monotherapy. Cells 
were treated with TMZ (150 µM) or TRAIL (100 ng/ml) for 96 h followed by cell viability measurement. Data show cell survival relative 
to control values of 100% (mean ± SEM from n = 3 independent experiments). E and F. Cell lines in the 3D PC space were color coded 
according to their responsiveness to TMZ and TRAIL, respectively. G. Performance of the response group separation in the 4D PC space 
by linear discriminant analysis (LDA) is shown by listing the amount of correctly classified cell lines.
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Subsequently, cell lines were defined treatment-
specifically as highly responsive (up to 30% survival), low 
responsive (30-80% survival) or resistant (>80% survival). 
According to the definition of response classes, the cell lines 
positioned in the PC space were color coded (Figure 2E, 2F). 
Interestingly, it appeared that within the 3D space, resistant 
cell lines seemed to be spatially separated from cell lines with 
higher responsiveness (Figure 2E, 2F). While visually this 
pattern was obvious, we tested whether this separation could 
likewise be achieved objectively by using linear discriminant 
analysis (LDA), an algorithm that aims to separate the 
responsiveness groups by hyperplanes in the 4D PC space. 
The separation of the response groups by this approach 
was highly accurate, with all cell lines correctly classified 
Figure 3: Case-specific predictions of TMZ and TRAIL monotherapy responsiveness in GBM cell lines. A. Workflow for 
determining the predictive power of the model using leave-one-out cross-validation (LOOCV). All predictions were performed in 4D PC 
space. B,C. 2D projections of the PC spaces calculated from combinations of 10 cell lines are shown for TMZ and TRAIL treatments. Circle 
sizes decrease with distance from the viewer, thereby providing information on the third PC dimension. Open circles represent the test 
cell lines, which were placed into the PC spaces according to their functional group values. D. Performance scores for correctly predicting 
cell line responses to TMZ and TRAIL monotherapy. E. Case-specific predictions on TMZ and TRAIL responsiveness allow the in silico 
identification of optimal treatment options. Treatment recommendations were made according to the highest predicted responsiveness to 
TMZ or TRAIL and validated against experimental data. Green background indicates cases where optimal treatment options could be 
identified. Red background indicates cases where the better treatment option could be missed.
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into their respective response groups for TMZ treatment 
responsiveness (Figure 2G). For TRAIL responsiveness, 
only one highly responsive cell line was identified, which 
was pooled with the next highest responsiveness group for 
all subsequent analyses. LDA correctly classified 10/11 cell 
lines (91%) for TRAIL responsiveness (Figure 2G). Taken 
together, these findings indicate that protein data of key cell 
death regulators together with information on their interplay 
can be employed to separate GBM cell lines according to 
their TMZ and TRAIL responsiveness.
Case specific predictions of TMZ and TRAIL 
monotherapy responsiveness allow the in silico 
identification of optimal treatments
We next investigated whether the above findings can 
assist in predicting the responsiveness of individual cell 
lines to TMZ or TRAIL. We hypothesized that conducting 
the above analyses with a reduced number of cell lines 
may be sufficient to generate a PC space that can be 
segmented into spatial regions that reflect different levels 
of treatment responsiveness. We conducted a leave-one-out 
cross validation (LOOCV) in which we used the data from 
10 cell lines and subsequently positioned the 11th cell line 
into the LDA segmented PC space. If the placed cell line 
(test cell line) was positioned within the correct response 
region, the prediction was considered to be correct 
(Figure 3A). A visualization of the results limited to the 
first two PCs for TMZ and TRAIL response predictions 
is shown in Figure 3B, 3C. The prediction accuracies are 
summarized in Figure 3D; this demonstrates that TMZ 
and TRAIL responsiveness can be predicted with high 
accuracy (73% and 82% correct predictions, respectively).
In situations where multiple treatment options are 
available, treatment decision tools are required to assist 
in pre-selecting the optimal treatment option. An optimal 
treatment in our case (TMZ vs. TRAIL) was defined as 
the treatment that induces higher amounts of cell death 
for a given cell line. If both drugs cause similar amounts 
of cell death, either treatment suggestion was considered 
acceptable. Predictions were considered to have failed when 
the model recommended the treatment option with a lower 
effect on cell viability than the alternative treatment option. 
The performance of the model as a treatment decision tool 
is shown in Figure 3E. Treatment recommendations for the 
11 cell lines were correct in 82% (9/11) of cases. These 
proof-of-concept results demonstrate that our modeling 
approach has the potential to identify best treatment options 
for individual cell lines with high accuracy.
Capability to predict synergistic responses to 
TMZ and TRAIL
It has previously been reported that combination 
therapy with TMZ/genotoxic agents and TRAIL may 
significantly enhance the responsiveness of highly 
treatment resistant cancer models, such as GBM cell lines 
[29–31]. We therefore next studied the responsiveness of 
the cell line panel to TMZ/TRAIL combination treatment. 
First, we investigated whether the response groups could 
be separated in the PC space and then we determined 
whether overall responsiveness as well as response 
synergies in these cell lines could be reliably predicted.
Overall, the responsiveness of the GBM cell line 
panel to TMZ/TRAIL treatment was improved when 
compared to the single agent treatments (Figure 4A, 
Figure 2D); this reduction in cell viability (Figure 4A) 
correlated with an increase in apoptotic cell death in 
TMZ and TRAIL-treated U251 cells, as evidenced by 
PARP cleavage and the prevention of such cleavage 
upon caspase inhibition (Supplementary Figure S1C), 
a significant increase in the number of Hoechst-labelled 
condensed nuclei (Supplementary Figure S1D), and 
caspase-3 substrate cleavage (Supplementary Figure 
S1E). No such cell death-related changes were evident in 
the treatment-resistant cell line, MZ294 (Supplementary 
Figure S1C, S1D, S1E). As with the single agent 
treatments, the response pattern to TMZ/TRAIL 
treatment was heterogeneous across the cell line panel, 
with both resistant and responsive cell lines identified 
(Figure 4A). Color coding the cell lines according to 
TMZ+TRAIL responsiveness again indicated that 
regions in the PC space appear to be associated with 
different levels of treatment responsiveness, and 
that these spatial regions can be separated by LDA 
(Supplementary Figure S2A, S1B). To test the predictive 
capacity of the model for TMZ+TRAIL combination 
treatment, we again conducted LOOCV (Supplementary 
Figure S2C). However, the responsiveness of only 6 
out of the 11 cell lines was predicted correctly (55%) 
(Supplementary Figure S2D).
Since the capacity of the model to predict cell line 
responsiveness to the dual treatment strategy of TMZ 
and TRAIL was limited, we next considered whether 
our modeling approach was better suited to study and 
predict response synergies. To this end, we first calculated 
the (CI) Value of each cell line using Webb’s fractional 
product method [56], which provided us with a ‘synergy 
score’ for the combination treatment for each cell line 
(Supplementary Table S4); this was then used to place 
the cell lines in the PC space. Using this approach, we 
obtained regions in the PC space that allowed us to 
separate the cell lines by response synergies (Figure 
4B). Furthermore, once we performed LOOCV using the 
CI Values, we found that we could successfully predict 
response synergies to TMZ and TRAIL combination 
therapy with 100% accuracy (Figure 4C, 4D). Taken 
together, these results indicate that while prediction 
accuracies for the overall responsiveness to TMZ and 
TRAIL were limited, apoptosis protein expression patterns 
together with our modeling approach, were particularly 
powerful in predicting response synergies.
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Accurate prediction of TRAIL sensitization by 
Bcl-2/Bcl-xL antagonist ABT-737
The above analyses demonstrated that it is possible 
to predict from baseline protein expression profiles 
whether individual cell lines will respond to TMZ or 
TRAIL monotherapy. Since many of the GBM cell lines 
were resistant to TMZ or TRAIL or only responded poorly, 
we next investigated if our systems modeling approach 
could be used to predict whether poorly responsive cell 
lines could be sensitized to treatment by ABT-737. ABT-
737 specifically antagonizes Bcl-2 and Bcl-xL, the major 
anti-apoptotic members of the Bcl-2 protein family, 
by binding to a hydrophobic groove of these proteins, 
thereby displacing bound activator BH3-only proteins and 
enabling the activation of pro-apoptotic Bax and Bak [57].
To generate predictions on which cell lines could 
be sensitized to TMZ or TRAIL by ABT-737, we first 
determined how the position of such cell lines in the PC 
space would change upon elimination of Bcl-2 and Bcl-
xL. This repositioning was determined from the PCA 
results and the cell lines’ protein profiles. The vector for 
the movement direction (Figure 5A) was determined by 
inverting and combining the coefficients of the FG for the 
Figure 4: Predicting the synergy of TRAIL and TMZ combined therapy. A. Cell survival following TMZ and TRAIL combined 
therapy. Cells were treated with TMZ (150 µM) and TRAIL (100 ng/ml) for 96 h and MTT assays were performed to assess cell viability. 
Data show cell survival relative to control values of 100% (mean ± SEM from n = 3 independent experiments). B. Cell lines in the 3D space 
were separated according to their Combination Index (CI) Value and color coded according to their response synergies to TMZ and TRAIL 
combined treatment. Visual inspection indicates the response regions are spatially separated. C. 2D projections of the PC spaces calculated 
from combinations of 10 cell lines are shown for TMZ/TRAIL combined treatments. Circle sizes decrease with distance from the viewer, 
thereby providing information on the third PC dimension. Open circles represent the test cell lines, which were placed into the PC spaces 
according to their CI Value. Note that the U251 cell line had to be grouped with the low responding cell lines in this analysis since it was 
alone in its response group. D. Performance scores for correctly predicting synergistic responses to TMZ/TRAIL combination therapy.
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Figure 5: Prediction and experimental validation of GBM cell line sensitization to TRAIL or TMZ treatment by ABT-737. 
A. A movement vector (red) was calculated by combining the weightings for the (Bcl-2+Bcl-xL+Mcl-1) functional group in the first 3 PCs. (i) and 
(ii) provide different perspectives on the vectors, compatible with 3D PC spaces for TMZ or TRAIL responsiveness. B. 3D PC spaces for TMZ and 
TRAIL responsiveness with movement vectors applied to test cell lines. The length of the movement vectors was calculated from the respective 
Bcl-2 and Bcl-xL content of the cell lines. Movement of treatment resistant cell lines towards regions populated by cell lines with higher treatment 
responsiveness predicts sensitization by the Bcl-2/Bcl-xL antagonist ABT-737. C, D, E. Experimental validation of predictions. Cell viability was 
measured for single and combination treatments. (C) Cells were treated with TMZ (150 µM) ± ABT-737 (1 µM) for 48 h. (D) Cells were treated 
with TRAIL (100 ng/ml) ± ABT-737 (1 µM) for 48 h. Data show cell viability (mean ± SEM from n = 3 independent experiments) in relation to 
untreated controls (100%). One-way ANOVA with Bonferroni comparisons was performed for statistical analysis. **p<0.01, ***p<0.001. ns = not 
significant. (E) Western blot analysis to confirm the successful knockdown of Bcl-2 and Bcl-xL. MZ18 and MZ304 cells were transfected with 
Bcl-2 and Bcl-xL esiRNA. F. siRNA depletion of Bcl-2 and Bcl-xL strongly sensitizes MZ18 but not MZ304 cells to TRAIL. Data show the number 
of PI+ cells (mean ± S.D. from triplicate samples) following treatment with TRAIL (100 ng/ml). Experiments were repeated with similar results.
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anti-apoptotic Bcl-2 proteins (Figure 2B); the distance 
moved depended on the amount of Bcl-2 and Bcl-xL 
that contributed to the (Bcl-2+Bcl-xL+Mcl-1) FG value 
in the respective cell lines (high amounts of Bcl-2 and 
Bcl-xL caused a more pronounced displacement). The 
resulting repositioning vectors were then applied to four 
representative cell lines that poorly responded to TMZ or 
TRAIL (MZ18, MZ294, MZ304, MZ327 cell lines and 
MZ18, U87, MZ304, MZ294 cell lines, respectively). 
For TMZ + ABT737 treatments, the movement vectors 
indicated that none of the cell lines would reposition closer 
to responding cell lines (Figure 5B), suggesting that ABT-
737 co-treatment would not sensitize these glioma cells to 
TMZ. For TRAIL + ABT737 treatments, the movement 
vectors indicated that MZ18 and U87, but not MZ294 and 
MZ304, cell lines would reposition closer to responding 
cell lines and thus be sensitized to TRAIL (Figure 5B).
These predictions were then validated experimentally. 
The selected cell lines were treated with either TMZ or 
TRAIL in the presence and absence of ABT-737 (1 µM) 
for 48 h. Cell viability measurements demonstrated that 
ABT-737 selectively sensitized MZ18 and U87 cells to 
TRAIL treatment, whereas ABT-737 did not sensitize any 
of the other cell lines to TMZ or TRAIL (Figure 5C, 5D). 
ABT-737 did not reduce cell viability on its own. These 
findings demonstrate that all predictions regarding ABT-
737-based sensitization could be validated (8/8), with our 
approach able to identify the subset of GBM cell lines 
that could be successfully sensitized to TRAIL by ABT-
737 co-treatment. To further validate these predictions, we 
used siRNA to knockdown Bcl-2 and Bcl-xL in MZ18 and 
MZ304 cells. As expected, our findings demonstrate that 
successful knockdown of Bcl-2 and Bcl-xL is sufficient 
to strongly sensitize MZ18 cells to TRAIL monotherapy. 
Our findings also demonstrate that, as predicted, Bcl-2 and 
Bcl-xL knockdown failed to notably raise the sensitivity of 
MZ304 cells to TRAIL monotherapy (<20% cell death). 
(Figure 5E, 5F). Overall, these findings demonstrate that 
the sensitizing effect of pharmacologically neutralizing 
anti-apoptotic Bcl-2 family members or by siRNA-based 
depletion can be accurately predicted by our approach.
DISCUSSION
Efficient induction of cell death is the aim of many 
anti-cancer therapies; thus, it follows that a cellular 
defect in cell death signaling pathways like apoptosis 
underlies one way in which these therapies can fail 
[32]. In apoptosis, death decisions are tightly controlled 
through multi-factorial and non-linear interplay of 
numerous regulatory proteins [58]; for this reason, in-
depth molecular analysis of any single protein, whether 
it be death-inducing or survival-promoting, is unlikely 
to yield an accurate prediction of drug responsiveness. 
Indeed, it is worth noting that no individual cell 
death regulating protein has so far been identified as 
a predictive or prognostic biomarker for GBM [59]. 
Instead, due to the complexity of apoptosis signaling, 
it seems rational that any potential insight gained from 
this cell death pathway should require analysis of all the 
key players involved. This, coupled with knowledge of 
how these players interact, has the potential to provide 
us with a much greater overview of a cell’s capability 
to undergo apoptosis when confronted with a therapy 
that ultimately aims to achieve this mode of cell death. 
In this study, we applied this theory to both intrinsic 
(TMZ) and extrinsic (TRAIL) apoptosis-inducing 
therapies and successfully separated our panel of GBM 
cell lines according to their treatment response with 
100% and 91% accuracy, respectively (Figure 2G). This 
indicates that the complexity of the apoptosis signaling 
network as a whole needs to be taken into account for the 
implementation of successful predictive and prognostic 
strategies in GBM.
The functional groups defined in our study represent 
low numbers of proteins logically inter-related according 
to their biological interplay. This approach towards 
systems modeling is notably simplistic when compared 
to alternative modeling strategies, such as deterministic 
mathematical models that build on the use of differential 
equations [60]. The modeling strategy chosen here 
has the distinct advantage of being more versatile and 
easy to implement, amend and extend going forward. 
For example, to build on our proof-of-concept study 
with subsequent translational studies, we could include 
additional independent variables that pertain, for example, 
to the sub-type of GBM, thereby gaining knowledge of 
the driver mutations and their effect on cell death/survival 
signals. Age, Karnofsky performance score, extent of 
surgical resection and other clinicopathological factors 
influencing prognosis could also be included [61].
Importantly, once our cell lines were distributed 
in the PC space according to their protein expression 
profiles, we found little evidence of cell line overlap or 
clustering, indicative of the widespread heterogeneity 
found between the FGs of each cell line. This mirrors the 
extensive molecular heterogeneity found between GBM 
patients [15, 16] and backs the theory that a ‘one-size-
fits-all’ approach to treating this disease, particularly with 
an apoptosis-targeted therapy, may not be valid [62]. 
Instead, in line with advocates of personalized medicine, 
it is conceivable that patients could be treated based on 
their unique set of molecular alterations in, or expression 
of, apoptosis regulators. For this, treatment decision tools 
such as ours will need to be developed and clinically 
validated in the future to assist in the pre-selection and 
stratification of patients for optimal therapies.
The prediction accuracy of our model was 73% 
and 82% for TMZ and TRAIL treatments, respectively. 
The higher performance score for TRAIL was likely 
attributable to the fact that we included all critical 
TRAIL signaling components in our model. Furthermore, 
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TRAIL-induced apoptosis is capable of proceeding 
independently of protein neo-synthesis, which suggests 
that baseline expression values for TRAIL signaling 
proteins is sufficient to predict the capacity of a cell to 
undergo TRAIL-induced apoptosis. The one obvious 
omission to the model, which may resolve any prediction 
error, is quantitative input for the TRAIL decoy receptors 
(DcR1 and DcR2). However, the level of decoy receptor 
expression in glioma cells is reportedly very low and 
therefore unlikely to account for TRAIL resistance [63]. Of 
course, we can’t exclude the possibility that other cellular 
events could be influencing TRAIL susceptibility, such 
as survival signaling [64] and induction of cytoprotective 
autophagy [65, 66]. For example, it is now known that 
in some cellular contexts TRAIL can engage NFkB, PKB/
Akt and MAPKs signaling pathways, thereby contributing 
to cancer cell proliferation and migration as well as 
resistance to TRAIL-induced apoptosis [67]. Improving 
the predictive capacity for TMZ from baseline protein 
expression profiles may prove to be more difficult given 
that apoptosis occurs as a consequence of DNA damage 
and requires transcriptional and translational responses 
[4]. However, in this regard, future model extensions 
could take into account additional upstream events, such 
as DNA repair activity and p53 status as a main driver of 
transcriptional BH3-only protein induction [68, 69].
Cell line responsiveness to TMZ and TRAIL 
varied substantially, with individual cell lines frequently 
responding differently to TMZ and TRAIL monotherapy. 
This gave us the opportunity to assess whether our model 
could be exploited as a treatment decision tool. The 
prediction accuracy of our model was 82%, with treatment 
recommendations correct 9 times out of 11. However, it 
should be noted that few cell lines responded well to either 
treatment, highlighting once again the profound resistance 
of glioma cells to apoptotic stimuli and the need for more 
effective and rational combination therapies. In recent 
years, there has been an abundance of studies reporting 
on mechanisms to overcome apoptosis resistance in 
GBM for both established and novel therapies [24–32]. 
For the purpose of this study, we first focused on TMZ 
and TRAIL combination therapy, which in theory has 
the propensity to activate both the intrinsic and extrinsic 
apoptotic pathways, thereby enhancing both the likelihood 
of apoptosis induction as well as the strength of the 
apoptotic signal. In this case, our model only predicted 
the responsiveness of cell lines to TMZ+TRAIL with 55% 
accuracy (Supplementary Figure S2D). This indicates 
that other factors need to be taken into account to more 
accurately predict TMZ+TRAIL responsiveness. Such 
factors may include additional molecular information, 
such as genetic alterations, resulting in the inactivation 
of apoptosis proteins or that may affect death/survival 
signals. Similarly, additional pathway cross-talk and/or 
the potentiation of signaling processes may need to be 
taken into account. For example, to address the synergistic 
manner in which TMZ and TRAIL come together to 
enhance apoptosis and in an attempt to determine whether 
knowledge of this synergy improves the predictive power 
of the model in co-treatment scenarios, we calculated the 
CI Value of each cell line [57]; this in turn allowed us 
to predict with 100% accuracy the response synergies of 
individual cells lines to TMZ+TRAIL (Figure 4C, 4D).
Strikingly, we were also able to predict cell line 
sensitivity to TMZ and TRAIL upon their co-treatment 
with ABT-737 with 100% accuracy, highlighting that the 
consequences of a targeted intervention are captured by 
our approach; this finding was further validated by siRNA 
depletion of Bcl-2 and Bcl-xL. In light of the recent FDA 
approval of the first Bcl-2 inhibitor, Venetoclax (ABT-
199), for patients with chronic lymphocytic leukemia 
with the 17p deletion, as well as the encouraging phase 
I-III clinical trials in development for Venetoclax as a 
monotherapy and/or combination therapy for various 
types of cancer [70], our capability to accurately predict 
the treatment outcome of a targeted intervention within 
the apoptosis signaling cascade is a particularly pertinent 
finding. Interestingly, ABT-737 failed to sensitize any 
GBM cell line to TMZ therapy, whilst in contrast MZ18 
and U87 cells were sensitized to TRAIL. On the one hand, 
this may suggest that the expression levels of Bcl-2 and 
Bcl-xL are irrelevant to TMZ resistance, at least within the 
expression ranges observed in our cell line panel, but on 
the other hand it also highlights the potential superiority of 
TRAIL-based therapies. TRAIL has long been perceived 
as a potential attractive chemotherapeutic agent, since 
it can kill cancer cells without conferring significant 
toxicity to normal cells [21], however, to date, no TRAIL-
based therapy has demonstrated both potency and lack of 
systemic toxicity in any clinical trial [17, 22, 23]. Besides 
the limitations of previous TRAIL-based therapeutics, 
that are now being addressed in the design of superior 2nd 
generation receptor ligands [71, 72], it is our conjecture 
that the lack of patient pre-selection in these trials may 
have contributed to their disappointing outcomes.
With the era of personalized medicine looming, 
our approach, if validated translationally in subsequent 
studies, could help to stratify patients for TRAIL mono- 
or combination therapies. Such translational studies would 
initially require use of large-scale quantitative protein 
data from fresh or archived GBM tissue as well as the 
identification of high quality antibodies for the use of high 
through-put screening methods, like reverse phase protein 
or tissue micro arrays. For a clinical setting, our model 
could be refined to focus on cancer stem cell populations, 
believed to be the tumor initiating cells that drive the 
growth, progression and invasion of GBMs as well as 
their post-treatment recurrence [73–75]. In this regard, 
quantitative protein analysis of this highly tumorigenic 
sub-population of cells could provide us with crucial 
insight into whether tumor cells not surgically removed 
will respond to treatment.
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In conclusion, we have described the first pre-
clinical proof-of-principle study that merges quantitative 
protein-based analysis of apoptosis signaling networks 
with data- and knowledge-driven mathematical systems 
modeling to predict treatment responsiveness of GBM cell 
lines to various apoptosis-inducing stimuli. Furthermore, 
we have shown that a systems biology-based approach 
could assist in personalizing treatment decisions in GBM 
to optimize cell death induction.
MATERIALS AND METHODS
Materials
TMZ was purchased from Sigma-Aldrich Ireland 
Ltd (Dublin, Ireland). Human recombinant TRAIL was 
purchased from Enzo Life Science (UK) Ltd (Exeter, 
United Kingdom). ABT-737 was purchased from Biorbyt 
(Riverside, United Kingdom), and Bcl-2 and Bcl-xL 
esiRNAs were purchased from Sigma-Aldrich Ireland Ltd 
(Dublin, Ireland).
GBM cell lines
GBM cell lines A172, U87, U251, U343 and 
U373 are commercially available from the ATCC. GBM 
cell lines MZ18, MZ51, MZ294, MZ304, MZ327, and 
MZ256 were kindly donated by Professor Donat Kögel of 
Johann Wolfgang Goethe University Hospital, Frankfurt, 
Germany and have previously been characterized [76]. 
The cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% heat-inactivated fetal calf 
serum, 100 U/ml penicillin and 100 mg/ml streptomycin 




In order to determine the basal expression level of 
apoptotic proteins, GBM cell lines were homogenized 
in lysis buffer containing 0.5 mmol/l Tris-HCl (pH6.8), 
2% SDS (w/v), 10% glycerine (w/v), and protease and 
phosphatase inhibitor cocktails (Sigma-Aldrich). After 
determining the protein concentration of samples using 
a BCA protein assay (Pierce, Rockford, IL, USA), 20 μg 
samples were boiled in gel-loading buffer and separated 
on 10-15% SDS-PAGE gels. Proteins were transferred 
to nitrocellulose membranes using the iBlot gel transfer 
device (Life Technologies, Invitrogen, Paisley, Scotland). 
The membranes were blocked in 5% non-fat milk in 
TBST for 1 h at room temperature prior to being incubated 
with primary antibodies overnight at 4°C. The following 
primary antibodies were used: rabbit polyclonal Apaf-1 
(Cat# 16941, Millipore); rabbit polyclonal Bak (Cat# sc-
832, Santa Cruz); rabbit polyclonal Bax (Cat# 06-499, 
Upstate Biotechnology); mouse monoclonal Bcl-2 
(Cat# sc-509, Santa Cruz); mouse monoclonal Bcl-xL 
(Cat# sc-8392); rabbit polyclonal Bid (Cat# 2002, Cell 
Signaling); rabbit monoclonal Bim (Cat# 2933, Cell 
Signaling); rabbit polyclonal caspase-3 (Cat# 9662, 
Cell Signaling); mouse monoclonal caspase-8 (Cat# 
ALX-804-242, Enzo Life Sciences); rabbit polyclonal 
caspase-9 (Cat# 9502, Cell Signaling); mouse monoclonal 
cFLIP (Cat# ALX-804-428, Enzo Life Sciences); mouse 
monoclonal FADD (Cat# 610399, BD Biosciences); mouse 
monoclonal Mcl-1 (Cat# 559027, BD Biosciences); mouse 
monoclonal Noxa (Cat# 13654, Abcam); rabbit polyclonal 
PUMA (Cat# 3041, ProSci Incorporated); mouse 
monoclonal SMAC/DIABLO (Cat# 2954, Cell Signaling); 
and mouse monoclonal XIAP (Cat# 610763, BD 
Biosciences); and mouse monoclonal β-actin (Cat# A5441, 
Sigma-Aldrich). Membranes were then washed three 
times with TBST for 5 min prior to being incubated with 
peroxidase-conjugated secondary antibodies (anti-mouse 
or anti-rabbit; Millipore) for 1 h at room temperature. 
Protein bands were visualized using the Immobilin western 
chemiluminescence HRP substrate (Millipore) and images 
were captured using a LAS-4000 imager equipped with 
a cooled 12 bit digital CCD camera (Fujifilm UK Ltd, 
Bedfordshire, UK). To guarantee accurate quantifications, 
special care was taken not to over-expose the protein 
bands. Densitometry was carried out on 12-bit raw images 
using ImageJ 1.4.10 software (National Institute of Heath, 
Bethesda, MD, USA; http://rsb.info.nih.gov/ij). For each 
protein, the integrated density of the signal was measured, 
corrected for background signals and normalized to a 
β-actin loading control. Standard curves from HeLa cell 
extracts (5-20 mg) were run concurrently with the GBM 
cell line extracts to ensure linearity of the signal detection 
range. The absolute concentration of most proteins of 
interest was previously determined in HeLa cells [77–79], 
so that HeLa cell signals could be used to calculate protein 
concentrations in GBM cell lines. Quantifications were 
carried out on at least 3 independent membranes. Cleavage 
of caspase-8 and caspase-3 was also assessed in A172 and 
MZ304 cells following TRAIL treatment (100 ng/ml) in 
the presence of the caspase inhibitor, zVAD-fmk (150 
μM; 30 min pre-treatment) for 24 and 96 h, respectively. 
Cleavage of PARP was assessed in MZ294 and U251 cells 
following the combined treatment of TRAIL (100 ng/ml) 
+ TMZ (150 μM) in the presence or absence of zVAD-fmk 
(150 μM; 30 min pre-treatment) for 96 h.
Flow cytometry
The basal surface expression of DR4 and DR5 
were assessed using a BD LSR II flow cytometer (BD 
Biosciences). Briefly, 1 x 105 cells were seeded into 
6 well plates and allowed to adhere overnight. Cells 
were then harvested with trypsin-EDTA and pelleted by 
centrifugation at 1200 rpm for 5 min at 4°C. Following 
incubation with a blocking buffer (0.5% BSA) on ice for 
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20 min, cells were incubated with a mouse monoclonal 
antibody for DR4 (Cat# ab13890, Abcam; 1:100 dilution) 
or DR5 (Cat# ALX-804-914-0100, Enzo life sciences; 
1:100 dilution) for 30 min, pelleted and washed x 3 with 
PBS, and then incubated with a secondary anti-mouse 
FITC-conjugated antibody (Life Technologies, Invitrogen, 
Paisley, Scotland; 1:200 dilution) for 30 min in the dark. 
Controls were stained with secondary antibody only. 
FITC was excited at 488 nm and fluorescence emission 
was collected in the FL1 channel through a 520 nm band-
pass filter. A total of 1 x 104 gated cells were acquired 
for each cell line. The relative expression of DR4 and 
DR5 was determined by comparison of specific staining 
intensities compared to individual cell line negative 
controls. For cell death measurements, flow cytometry was 
used to assess the number of AnnexinV+ cells following 
treatment with TRAIL (100 ng/ml) or TRAIL+TMZ (150 
μM) in the presence or absence of zVAD-fmk (150 μM; 
30 min pre-treatment) for 96 h as well as the number 
of PI+ cells following transfection with Bcl-2/Bcl-xL 
siRNA and treatment with TRAIL (100 ng/ml) for 48 h. 
Briefly, cells were seeded into 6-well plates and allowed 
to adhere overnight. Following appropriate treatment 
conditions, cells were pelleted and incubated in 100μl 
of binding buffer (10 nM HEPES, 135 nM NaCl, 5 mM 
CaCl
2
) containing AnnexinV- FITC conjugate (5 μl/ml) 
(BioVision, Moutain View, CA, USA) for 10 min on ice 
in the dark or in DMEM containing PI (1.33 μg/ml) for 15 
min at 37°C. FITC was excited at 488 nm and fluorescence 
emission was collected in the FL1 channel through a 
520 nm band-pass filter. PI was excited at 561 nm and 
fluorescence emission was collected through a 605/40 nm 
band-pass filter and a 570 nm long pass filter. A total of 
1 x 104 gated cells were acquired for each cell line.
Cell transfection
To downregulate Bcl-2 and Bcl-xL protein 
expression, we used endoribonuclease-prepared small 
interfering RNAs (esiRNAs), which are comprised of a 
heterogeneous mixture of siRNAs that all target the same 
mRNA sequence (Cat# EHU135281 and EHU087041, 
Sigma-Aldrich). Briefly, MZ18 and MZ304 cells were 
transfected with 1 μg of Bcl-2 esiRNA and 1 μg of Bcl-
xL esiRNA for 4 h using LipofectamineTM 2000 in 
antibiotic-free Opti-MEM medium (Life Technologies, 
Invitrogen, Paisley, Scotland). Following this incubation 
period, the transfection mixture was replaced with fresh 
DMEM and the cells were allowed to recover for 48 h, 
after which they were used for experiments.
Cell viability measurements
GBM cell lines were seeded into 96-well plates 
(2000 cells/well) and allowed to adhere overnight. To 
validate cell line responsiveness to TMZ and TRAIL 
monotherapy, cells were treated at clinically-informed 
“maximum effect” (Emax) conditions and accordingly 
were treated with TMZ (150 µM) or TRAIL (100 ng/
ml) for 96 h. To confirm cell lines responsiveness to 
TRAIL and TMZ combined therapy, cells were treated 
with TRAIL (100 ng/ml) and TMZ (150 µM) for 96 h. 
To substantiate the sensitization of cell lines to TRAIL or 
TMZ with ABT-737, cells were either treated with TRAIL 
(100 ng/ml) in the presence or absence of ABT-737 (1 µM) 
for 48 h or with TMZ (150 µM) in the presence or absence 
of ABT-737 (1 µM) for 48 h. Following treatment, cells 
were incubated with thiazolyl blue tetrazolium bromide 
(MTT; 5mg/ml; Sigma-Aldrich Ireland Ltd) for 4 h at 
37°C, after which the medium was aspirated and replaced 
with DMSO (200 µl). The absorbance of each sample was 
measured at 560 nm using a microplate reader (GENios, 
Tecan, Mannedorf, Switzerland). MTT is a yellow 
tetrazole that is converted to dark blue/purple formazan 
by mitochondrial dehydrogenase of living cells. Thus, 
the absorbance value for each sample was considered 
proportional to the number of viable cells.
Hoechst staining
MZ294 and U251 cells were stained with Hoechst 
33258 (1 μg/ml) for 20 min. Changes in nuclear 
morphology were detected by epifluorescence microscopy 
(Nikon Eclipse TE300). Normal bright field images were 
taken to examine morphological changes, such as cell 
shrinkage and membrane blebbing.
Caspase-3 substrate cleavage
DEVDase (Caspase-3-like) activity was determined 
fluorometrically using carbobenzoxy-Asp-Glu-Val-
Asp-7-amino-4-methyl-coumarin (DEVD-AMC) as 
substrate. Cleavage of DEVD-AMC to liberate free 
AMC was monitored by measuring fluorescence after 1 
and 2 h intervals. Protein content was determined using 
Pierce Coomassie Plus Protein assay reagent (Perbio, 
Northumberland, UK). Caspase activity is expressed as a 
change in fluorescent units per hour and per microgram 
protein.
Statistical analysis
Student’s t-test or one-way ANOVA with post hoc 
Bonferroni test were performed to identify statistically 
significant differences between treatment groups. P-values 
are indicated in the figure panels and legends.
Data processing and analysis for knowledge- and 
data-driven systems modeling
All data processing and analysis was performed 
using a programming code developed for MATLAB 
2007b (The Mathworks, UK), equipped with the statistics 
toolbox; a detailed description of the procedures has 
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previously been published [37]. In brief, following the 
integration of protein expression data into functional 
groups, a PCA was performed [38, 39]. PCs with 
eigenvalues above 1 were retained, according to the 
Kaiser criterion [80, 81]. Scatter plots were generated 
from the first three PCs to visualize the data. LDA [82] 
was employed to determine the accuracy of response 
class separations in the PC space. LOOCV was applied 
to iteratively test the prediction capacity of the model 
for the entire cell line ensemble. LDA was applied after 
each iteration to determine if the test cell lines positioned 
in the PC space region that corresponded to its drug 
responsiveness. To predict sensitization effects of ABT-
737 in co-treatment scenarios, the protein values for the 
target proteins, Bcl-2 and Bcl-xL, were set to zero and the 
re-positioning of cell lines of choice in the PC space was 
investigated. Re-positioning towards PC space regions 
of higher responsiveness were interpreted as a prediction 
for successful sensitization. A detailed description for this 
procedure is available in [37].
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